GlassScriptPhysician profile
Paul Lecuyer
NPI 1427161298
$865.28
in general payments reported to CMS, 2019-2025
14 companies · $90.84 in 2025
The $90.84 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.35 · 2020: $105 · 2021: $147 · 2022: $58.32 · 2023: $138 · 2024: $301 · 2025: $90.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.32 | 2021-2025 | |
| Medtronic, INC. | $101.93 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $98.74 | 2020-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $52.35 | 2019-2020 | |
| Pfizer INC. | $46.76 | 2021-2023 | |
| Glaxosmithkline, LLC. | $46.14 | 2020-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $46.10 | 2021-2023 | Wegovy |
| Allergan, INC. | $35.85 | 2020 | |
| Verity Pharmaceuticals INC. | $32.87 | 2025 | Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.02 | 2022-2023 | Xifaxan |
| Inspire Medical Systems, INC. | $17.44 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $15.86 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2024 | Eliquis |
| Sumitomo Pharma America, INC. | $14.61 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lecuyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.